Recurrence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Journal of Urology

• Publication date

  2000-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(05)67523-4PMID 10799163
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Recurrence, progression and survival in bladder cancer. A retrospective analysis of 232 patients with greater than or equal to 5-year follow-up.

  2010cited by this paper
• The efficacy of intravesical BCG in the treatment of patients with high risk superficial bladder cancer

  2006cited by this paper
• Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder.

  1999cited by this paper
• Zystektomie beim schlecht differenzierten T1-Harnblasenkarzinom - oft zu früh?

  1998cited by this paper
• T1-Blasenkarzinom: Indikation zur transurethralen Elektroresektion oder zur primären radikalen Zystektomie?

  1997cited by this paper
• Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder.

  1996cited by this paper
• Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder.

  1996cited by this paper
• BCG in perspective: advances in the treatment of superficial bladder cancer.

  1995cited by this paper
• Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.

  1995cited by this paper
• Bacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term results.

  1995cited by this paper
• Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.

  1994cited by this paper
• Results of transurethral resection and intravesical doxorubicin prophylaxis in patients with T1G3 bladder cancer.

  1994cited by this paper
• Experimentelle und klinische Untersuchungen zur Biologie des Harnblasenkarzinoms

  1993cited by this paper
• Dissecting the immunobiological effects of Bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon.

  1993cited by this paper
• Bacillus Calmette-Guerin therapy for high risk stage T1 superficial bladder cancer.

  1992cited by this paper
• Intravesical therapy: does it affect the natural history of superficial bladder cancer?

  1992cited by this paper
• Intravesical therapy: does it affect the natural history of superficial bladder cancer?

  1992cited by this paper
• Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup.

  1992cited by this paper
• Management of stage T1 superficial bladder cancer with intravesical bacillus Calmette-Guerin therapy.

  1992cited by this paper
• Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder.

  1991cited by this paper
• Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients.

  1991cited by this paper
• Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion.

  1991cited by this paper
• A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?

  1991cited by this paper
• Factors affecting survival in primary superficial bladder cancer.

  1990cited by this paper
• The T1 bladder tumor.

  1990cited by this paper
• The role of radical cystectomy in the management of high grade superficial bladder cancer (PA, P1, PIS and P2)

  1990cited by this paper
• The pT1 G3 bladder tumour.

  1989cited by this paper
• Bladder tumors invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression.

  1989cited by this paper
• Intracavitary treatment of transitional cell carcinoma of the bladder: questions and lessons after 27 years of experience.

  1989cited by this paper
• Intravesical mitomycin C instillation as a prophylactic treatment of superficial bladder tumor.

  1989cited by this paper
• Chemotherapy for carcinoma in situ of the bladder.

  1988cited by this paper
• Radical cystectomy for historical and pathologic T1, N0, MO (stage A) transitional cell cancer: Need for adjuvant systemic chemotherapy?

  1988cited by this paper
• Radical cystectomy for historical and pathologic T1, N0, M0 (stage A) transitional cell cancer. Need for adjuvant systemic chemotherapy?

  1988cited by this paper
• Grading in superficial bladder cancer. (1). Morphological criteria.

  1988cited by this paper
• Radical cystectomy--often too late?

  1987cited by this paper
• Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor?

  1987cited by this paper
• Long-term effect of intravesical bacillus Calmette-Guerin on flat carcinoma in situ of the bladder.

  1986cited by this paper
• The use of bacillus Calmette-Guerin in the therapy of bladder carcinoma in situ.

  1985cited by this paper
• Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa.

  1983cited by this paper
• Cystectomy for superficial bladder cancer.

  1981cited by this paper
• Five‐year follow‐up results of a collaborative study of therapies for carcinoma of the bladder

  1977cited by this paper
• Suppression of tumor growth at the site of infection with living Bacillus Calmette-Guérin.

  1971cited by this paper

• Short-term outcomes comparison of KangDuo 2.0 and Da Vinci Xi in radical cystectomy

  2025cites this paper
• Intratumoral PD1+CD38+Tim3+ CD8+ T Cells in Pre-BCG Tumor Tissues Are Associated with Poor Responsiveness to BCG Immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer

  2023cites this paper
• Highlights into historical and current immune interventions for cancer.

  2023cites this paper
• ROLE OF AGE, GENDER, AND TOBACCO IN CAUSING BLADDER CANCER AND PATHOLOGICAL STUDY OF BLADDER CANCER IN KPK

  2023cites this paper
• High-Grade Non-Muscle Invasive Bladder Cancer: When to Move to Early Radical Cystectomy?

  2021cites this paper
• Bacillus Calmette–Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections

  2019cites this paper
• Bladder preservation approach versus radical cystectomy for high-grade non-muscle-invasive bladder cancer: a meta-analysis of cohort studies

  2018cites this paper
• Chapter 20 – Immunotherapy: Bacille Calmette–Guérin

  2018cites this paper
• A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy-A single-institution experience.

  2017cites this paper
• WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach

  2017cites this paper
• Clinico-pathological Study of Bladder Cancer in a Tertiary Care Center of South India and Impact of Age, Gender, and Tobacco in Causing Bladder Cancer: A Single Center Experience

  2016cites this paper
• Bacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive Disease

  2015cites this paper
• Pyuria predicts poor prognosis in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin.

  2015cites this paper
• Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR?

  2015cites this paper
• New and contemporary markers of prognosis in nonmuscle invasive urothelial cancer

  2015cites this paper
• Management of BCG Recurrent Bladder Cancer

  2015cites this paper
• Mixed low- and high-grade non-muscle-invasive bladder cancer: a histological subtype with favorable outcome

  2015cites this paper
• EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines.

  2014cites this paper
• Optimal Treatment of Non-Muscle Invasive Urothelial Carcinoma Including Perioperative Management Revisited

  2014cites this paper
• Introduction and first clinical application of a simplified immunohistochemical validation system confirms prognostic impact of KI-67 and CK20 for stage T1 urothelial bladder carcinoma: single-center analysis of eight biomarkers in a series of three hundred six patients.

  2013cites this paper
• When the Conservative Treatment in High-Risk Non-Muscle Invasive Bladder Cancer Patients should be Abandoned

  2013cites this paper
• The optimal management of T1 high-grade bladder cancer.

  2013cites this paper
• Determining the role of cystectomy for high-grade T1 urothelial carcinoma.

  2013cites this paper
• Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system.

  2013cites this paper
• Guidelines on Muscle-invasive and Metastatic Bladder Cancer

  2013influential citation
• Dendritic cells in blood and urine samples from bladder cancer patients undergoing BCG immunotherapy.

  2013cites this paper
• Immediate radical cystectomy vs conservative management for high grade cT1 bladder cancer: is there a survival difference?

  2012cites this paper
• Clinicopathological Analysis of Patients with Nonmuscle-Invasive Bladder Cancer Who Underwent Radical Cystectomy

  2012cites this paper
• Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection.

  2012cites this paper
• Loss of aquaporin 3 protein expression constitutes an independent prognostic factor for progression-free survival: an immunohistochemical study on stage pT1 urothelial bladder cancer

  2012cites this paper
• Predictive Biomarkers of Bacillus Calmette-Guérin Immunotherapy Response in Bladder Cancer: Where Are We Now?

  2012cites this paper
• Bacille Calmette-Guérin ( BCG ) for the treatment of superficial bladder cancer . A critical analysis of 25 years ' experience with various therapeutic schedules

  2012cites this paper
• Early vs delayed radical cystectomy for ‘high‐risk’ carcinoma not invading bladder muscle: delay of cystectomy reduces cancer‐specific survival

  2011cites this paper
• Intravesical mitomycin C combined with hyperthermia for patients with T1G3 transitional cell carcinoma of the bladder.

  2011cites this paper
• The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer

  2011cites this paper
• Usefulness of the Spanish Urological Club for Oncological Treatment scoring model to predict nonmuscle invasive bladder cancer recurrence in patients treated with intravesical bacillus Calmette-Guérin plus interferon-α.

  2011cites this paper
• Mesanenin mikropapiller tip değişici epitel hücreli karsinomu klinik, histolojik ve immünohistokimyasal özellikler: Olgu sunumu

  2011cites this paper
• Management of pT1G3 Bladder Cancer

  2011cites this paper
• Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin

  2011cites this paper
• Long‐term follow‐up of T1 high‐grade bladder cancer after intravesical bacille Calmette‐Guérin treatment

  2011cites this paper
• EARLY VS DELAYED RADICAL CYSTECTOMY FOR ‘HIGH‐RISK’ CARCINOMA NOT INVADING BLADDER MUSCLE: DELAY OF CYSTECTOMY REDUCES CANCER‐SPECIFIC SURVIVAL

  2011cites this paper
• Clusterin Immunoreactivity as a Predictive Factor for Progression of Non-Muscle-Invasive Bladder Carcinoma

  2010cites this paper
• Is T1G3 bladder cancer having a definite muscle layer in TUR specimens a highly progressive disease?

  2010cites this paper
• An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer.

  2010cites this paper
• Management of superficial bladder carcinoma: time to rethink the treatment strategies in the era of orthotopic neo-bladder.

  2010cites this paper
• Prognostic value of histopathological tumour growth patterns at the invasion front of T1G3 urothelial carcinoma of the bladder

  2009cites this paper
• Prognostic significance of non-papillary tumor morphology as a predictor of cancer progression and survival in patients with primary T1G3 bladder cancer

  2009cites this paper
• Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model.

  2009cites this paper
• Guidelines on Bladder Cancer Muscle-invasive and Metastatic

  2008influential citation
• equine sarcoids – Part 2 : current treatment modalities Equine sarcoïden – Deel 2 : huidige behandelingsmogelijkheden

  2008cites this paper
• Early versus deferred cystectomy for initial high-risk pT1G3 urothelial carcinoma of the bladder: do risk factors define feasibility of bladder-sparing approach?

  2008cites this paper
• Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high‐grade bladder cancer? A long‐term follow‐up of a randomized study

  2008cites this paper
• Intravesical Bacillus Calmette-Guérin Therapy for T1 Superficial Bladder Cancer

  2008cites this paper
• The optimal management of T1G3 bladder cancer

  2008cites this paper
• Bacillus Calmette-Guérin in the management of superficial bladder cancer

  2008cites this paper
• Experiencia de 5 años en el manejo del carcinoma vesical superficial de células transicionales con BCG en el Centro Médico Nacional “20 de Noviembre” ISSSTE

  2008cites this paper
• A meta-analysis of randomized trials of maintenance bacillus Calmette-Guerin instillation efficacy against recurrence of T1G3 bladder tumor

  2008cites this paper
• Prävalenz von Lymphknotenmetastasen beim nicht muskelinvasiven Blasenkarzinom

  2008cites this paper
• Tumour growth inhibition by an imidazoquinoline is associated with c‐Myc down‐regulation in urothelial cell carcinoma

  2008cites this paper
• Organ erhaltende Therapie oder initiale Zystektomie beim T1G3-Harnblasenkarzinom: Welche Faktoren helfen bei der Therapieentscheidung?

  2008cites this paper
• Editorial Comment

  2007cites this paper
• The best treatment for high-grade T1 bladder cancer is cystectomy.

  2007cites this paper
• Bacillus Calmette-Guerin and bladder cancer.

  2007cites this paper
• Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.

  2007cites this paper
• The difference in the prognosis and characteristics between the progressive and primary muscle-invasive bladder cancer treated with radical cystectomy

  2007cites this paper
• Treatment paradigm shift may improve survival of patients with high risk superficial bladder cancer.

  2007cites this paper
• Bladder sparing approach for initial T1G3 bladder cancer: Do multifocality, size of tumor or concomitant carcinoma in situ matter? A long‐term analysis of 132 patients

  2007cites this paper
• Difficult decisions in urologic oncology: management of high-grade T1 transitional cell carcinoma of the bladder.

  2007cites this paper
• Optimal Management of the T 1 G 3 Bladder Cancer

  2007cites this paper
• Controversial issues and optimal management of stage T1G3 bladder cancer

  2006cites this paper
• Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations.

  2006cites this paper
• Is a second transurethral resection necessary for newly diagnosed pT1 bladder cancer?

  2006cites this paper
• Management of stage T1 tumors of the bladder: International Consensus Panel.

  2005cites this paper
• Optimal management of the T1G3 bladder cancer.

  2005cites this paper
• A second look at the pT1 G3 bladder tumour.

  2005cites this paper
• Das kontrovers diskutierte Tumorstadium pT1G3

  2005cites this paper
• Lymph node metastases in non‐muscle invasive bladder cancer are correlated with the number of transurethral resections and tumour upstaging at radical cystectomy

  2005cites this paper
• Radiochemotherapy after transurethral resection is an effective treatment method in T1G3 bladder cancer.

  2005cites this paper
• Initial tumor stage and grade as a predictive factor for recurrence in patients with stage T1 grade 3 bladder cancer.

  2004cites this paper
• T1G3 bladder cancer – Indications for early cystectomy

  2004cites this paper
• Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy?

  2004cites this paper
• Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1).

  2004cites this paper
• TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.

  2004cites this paper
• Prognosis of T1G3 Tumors: Clinical Factors

  2004cites this paper
• Management of clinical T1 bladder transitional cell carcinoma by radical cystectomy.

  2004cites this paper
• A novel intravesical therapy for superficial bladder cancer in an orthotopic model: oncolytic reovirus therapy.

  2004cites this paper
• Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.

  2004cites this paper
• Bacillus Calmette–Guerin-refractory superficial bladder cancers: focus on pretreatment episodes

  2003cites this paper
• T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.

  2003cites this paper
• The management of stage T1 grade 3 transitional cell carcinoma of the bladder

  2003cites this paper
• A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival.

  2003cites this paper
• Evaluation and follow-up strategies for superficial bladder cancer.

  2003cites this paper
• High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).

  2003cites this paper
• Les tumeurs superficielles de vessie pT1G3 : à propos de 24 cas

  2003cites this paper
• [Superficial pT1G3 bladder tumor: 24 case reports].

  2003cites this paper
• The Management of T1G3 Bladder Cancer

  2002cites this paper
• Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience.

  2002cites this paper
• Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours.

  2002cites this paper
• Contemporary management of stage T1 transitional cell carcinoma of the bladder.

  2002cites this paper
• Recurrence and progression in stage T1G3 bladder tumour with intravesical bacille Calmette‐Guérin (Danish 1331 strain)

  2002cites this paper